Compare iShares MSCI Singapore ETF (EWS) vs Humana Inc (HUM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MSCI Singapore ETF vs Humana Inc — how do they compare? iShares MSCI Singapore ETF trades at $31.6 (market cap $1.49B), while Humana Inc trades at $431.03 (market cap $46.49B). The key difference: Humana Inc is far larger — about 31.2× iShares MSCI Singapore ETF's market cap, and Humana Inc pays a 0.91% dividend while iShares MSCI Singapore ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold iShares MSCI Singapore ETF for 45 Days and Humana Inc for 51 Days on average.
| EWS | HUM | |
|---|---|---|
Market Cap | $1.49B | $46.49B |
Volume | 2,142,305 | 2,567,704 |
Sector | Broad Market / Factor | Health |
52-Week High | $34.57 | $409.85 |
52-Week Low | $26.71 | $163.67 |
Typical Hold Time | 45 Days | 51 Days |
Enterprise Value | — | $53.84B |
Dividend Yield | — | 0.91% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EWS (iShares MSCI Singapore ETF) trades at $31.60, down 2.71% with bearish technical signals from moving averages and oscillators. The ETF recently hit 52-week highs amid Singapore's strong economic growth and AI momentum, attracting institutional interest including Amundi's 4.8% position increase. Key support sits at $31 with resistance at $32.
Outlook remains mixed with technical weakness offset by positive fundamental drivers. Investment opportunity lies in Singapore's economic resilience and AI-driven growth, though stretched valuations and bearish momentum present near-term risks. The ETF offers exposure to Asia's outperformance versus S&P 500 but faces volatility from regional economic sensitivity.
Humana (HUM) trades at $431.03, up 8.71% over the past day, reflecting strong momentum following a Barclays upgrade and positive earnings beats. The stock exhibits a bullish technical trend, with support at $378 and resistance at $394. Revenue has grown steadily from $92.9B in 2022 to $129.7B in 2025, though net income margins have compressed to 0.88%. Analyst consensus is a Buy with a $457.05 price target, and recent news highlights corporate initiatives and institutional investments.
The outlook for HUM is cautiously optimistic, driven by revenue growth and analyst support, but risks include margin pressure and regulatory scrutiny. Investment opportunity lies in execution of Medicare Advantage strategies, while key risks involve competitive pressures and potential fiduciary concerns highlighted in recent shareholder notices.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares MSCI Singapore ETF
EWS tracks the MSCI Singapore 25/50 Index, providing targeted exposure to large and mid-cap companies in Singapore. It is heavily weighted toward the financial, industrial, and real estate sectors, serving as a liquid tool for accessing Singapore's stable, dividend-oriented developed economy.
Read more on EWS →About Humana Inc
Humana is one of the largest private health insurers in the U.S. with a focus on administering Medicare Advantage plans. The firm has built a niche specializing in government-sponsored programs, with nearly all its medical membership stemming from individual and group Medicare Advantage, Medicaid, and the military's Tricare program. The firm is also a leader in stand-alone prescription drug plans for seniors enrolled in traditional fee-for-service Medicare. Humana offers employer-based plans primarily for small businesses along with specialty insurance offerings such as dental, vision, and life. Beyond medical insurance, the company provides other healthcare services, including primary-care services, at-home services, and pharmacy benefit management.
Read more on HUM →
